- Home
- AOSL vs ANAB Comparison
AOSL vs ANAB Comparison
Compare AOSL & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOSL
- ANAB
- Stock Information
- Founded
- AOSL 2000
- ANAB 2005
- Country
- AOSL United States
- ANAB United States
- Employees
- AOSL N/A
- ANAB N/A
- Industry
- AOSL Semiconductors
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- AOSL Technology
- ANAB Health Care
- Exchange
- AOSL Nasdaq
- ANAB Nasdaq
- Market Cap
- AOSL 616.9M
- ANAB 621.1M
- IPO Year
- AOSL 2010
- ANAB 2017
- Fundamental
- Price
- AOSL $27.29
- ANAB $26.94
- Analyst Decision
- AOSL Strong Buy
- ANAB Buy
- Analyst Count
- AOSL 3
- ANAB 10
- Target Price
- AOSL $30.67
- ANAB $49.00
- AVG Volume (30 Days)
- AOSL 218.5K
- ANAB 515.6K
- Earning Date
- AOSL 08-06-2025
- ANAB 08-04-2025
- Dividend Yield
- AOSL N/A
- ANAB N/A
- EPS Growth
- AOSL N/A
- ANAB N/A
- EPS
- AOSL N/A
- ANAB N/A
- Revenue
- AOSL $680,974,000.00
- ANAB $111,872,000.00
- Revenue This Year
- AOSL $7.05
- ANAB N/A
- Revenue Next Year
- AOSL $2.54
- ANAB $24.39
- P/E Ratio
- AOSL N/A
- ANAB N/A
- Revenue Growth
- AOSL 3.57
- ANAB 387.20
- 52 Week Low
- AOSL $15.90
- ANAB $12.21
- 52 Week High
- AOSL $53.29
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- AOSL 53.60
- ANAB 66.30
- Support Level
- AOSL $27.29
- ANAB $25.48
- Resistance Level
- AOSL $30.06
- ANAB $28.50
- Average True Range (ATR)
- AOSL 1.27
- ANAB 1.26
- MACD
- AOSL -0.18
- ANAB 0.02
- Stochastic Oscillator
- AOSL 32.60
- ANAB 70.23
About AOSL Alpha and Omega Semiconductor Limited
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).